Shilpa Medicare, Switzerland’s NXI Therapeutics ink deal for new chemical entity; shares up 3%

Under the agreement, Shilpa Medicare will develop and supply a novel asset targeting autoimmune and alloimmune disorders.

Leave a Reply

Your email address will not be published. Required fields are marked *